Northern Lights Fund Trust III Counterpoint Quantitative Equity ETF (NYSE: CPAI)

Dernières nouvelles pour Northern Lights Fund Trust III Counterpoint Quantitative Equity ETF (NYSE:CPAI)

Technology

Energy

Consumer Defensive

Consumer Cyclical

Other

Communication Services

Healthcare

Financial Services

Industrials

Utilities

The Fund seeks to achieve its investment objective by investing at least 80 percent of its assets (plus the amount of borrowings, if any) in common stocks and American Depositary Receipts (ADRs). The Fund holds at least 50 U.S. listed stocks or American Depository Receipts (ADRs). The stocks selected are of companies of any market capitalization and are among the highest-ranking stocks as determined by quantitative models..

Genedx Holdings Corp

Abercrombie Fi

Bill Com Holdings Inc

Gray Television Inc

Zim Integrated Shipping Servic

Navios Maritime Partners L P Com Unit Lpi

Hertz Global Holdings Inc

Vital Farms Inc.

Dell Techn-C

Targa Resources Corp.

T-mobile Us, Inc.

AT&T Inc.

Doximity, Inc.

Robinhood Markets Inc - A

Plains All Amer

Plains Gp Holdings Lp

Fox Corp. A

Cencora Inc

Mckesson Corp

Comstock Resources, Inc. Com

Sprouts Farmers Markets Inc.

Antero Resources Corporation

Expand Energy Corporation

Williams Companies Inc Ord

Bellring Brands Inc

Chewy, Inc., Class A

Virtu Financial Inc

Leggett & Platt Inc

Credo Technology Group Holding Ltd

Shoals Technologies Group Inc Cl A

Spotify Technology S.A.

Philip Morris International, Inc.

Mercadolibre Inc

Twilio Inc. Class A

Mercadolibre, Inc.

Counterpoint Quantitative Equity ETF

Bernstein analyst Richard Clarke maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Outperform and raises the price target from $290 to $360.

News

Price Target

Analyst Ratings

Bernstein Maintains Outperform on Royal Caribbean Gr, Raises Price Target to $360

WIIM

INTC

Intel shares are trading lower after reports suggesting CEO Lip-Bu Tan is evaluating whether to stop marketing the company's 18A chipmaking process to outside customers.

Wells Fargo analyst Steven Cahall maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Equal-Weight and raises the price target from $10 to $11.

Wells Fargo Maintains Equal-Weight on Warner Bros. Discovery, Raises Price Target to $11

Bernstein analyst Richard Clarke maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and raises the price target from $90 to $100.

SBUX

Bernstein Maintains Outperform on Starbucks, Raises Price Target to $100

Wells Fargo analyst Steven Cahall maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Underweight and raises the price target from $16 to $19.

SIRI

Wells Fargo Maintains Underweight on Sirius XM Holdings, Raises Price Target to $19

IPOs

CapsoVision IPO Opens For Trade At $5/Share; IPO Priced At $5/Share On 5.5M Shares

<a href="https://truthsocial.com/@realDonaldTrump/posts/114784170652465525" title="https://truthsocial.com/@realDonaldTrump/posts/114784170652465525">https://truthsocial.com/@realDonaldTrump/posts/114784170652465525</a>

Macro Economic Events

Macro Notification

Global

Economics

General

President Trump Posts On Truth Social "It is my Great Honor to announce that I have just made a Trade Deal with the Socialist Republic of Vietnam after speaking with To Lam.." "The Terms are that Vietnam will pay the United States a 20% Tariff on any and all goods sent into our Territory, and a 40% Tariff on any Transshipping. In return, Vietnam will do something that they have never done before, give the United States of America TOTAL ACCESS to their Markets for Trade."

Keybanc analyst Steve Barger maintains Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) with a Overweight and raises the price target from $50 to $60.

FLEX

Keybanc Maintains Overweight on Flex, Raises Price Target to $60

Keybanc analyst Michael Leshock maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Overweight and raises the price target from $29 to $40.

RKLB

Keybanc Maintains Overweight on Rocket Lab USA, Raises Price Target to $40

Keybanc analyst Michael Leshock maintains TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) with a Overweight and raises the price target from $1500 to $1700.

Keybanc Maintains Overweight on TransDigm Gr, Raises Price Target to $1700

Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) has outperformed the market over the past 15 years by 3.4% on an annualized basis producing an average annual return of 15.8%. Currently, Marriott International has a market capitalization of $76.23 billion. 
Buying $100 In MAR: If an investor had bought $100 of MAR stock 15 years ago, it would be worth $900.29 today based on a price of $276.84 for MAR at the time of writing.
<h3>Marriott International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751467597_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

SKYX New Patents Were Issued in the U.S., India, Japan, U.K. France, Germany, Italy, and Spain
SKYX's Patent Portfolio Includes Advanced Plug &amp; Play Smart Home Platforms, Enabling AI Capabilities and Eco System Integration, Home Safety Sensors, Ceiling Fan &amp; Heater, Lighting, Among Others
MIAMI, July 02, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) ("SKYX" or the "Company"), a highly disruptive smart home platform technology company with over 100 issued and pending patents globally and a growing portfolio of over 60 lighting and home décor websites, with a mission to make homes and buildings become smart, safe, and advanced as the new standard, today announces the issuance of 8 newly issued U.S. and global patents with now over 100 patents and pending applications with 45 issued patents. The new patents were issued in U.S., India, Japan, U.K., France, Germany, Italy, and Spain.
The Company's patent portfolio includes advanced and plug and play smart home platforms, enabling AI capabilities and ecosystem, home safety sensors, ceiling fan &amp; heater, lighting, among others.
SKYX's Total Addressable Market ("TAM") of over $500 billion, with its robust and versatile U.S. and global patent portfolio, creates tremendous Company value. The Company's U.S. and global patent portfolio of over 100 issued and pending patents, 45 of which are issued patents covers SKYX's advanced plug-and-play and smart home platform technologies for safety, smart home, AI, electrical, lighting and ceiling fan industries.

SKYX

SKYX Expands Global Smart Home Patent Portfolio With 8 New Patents Across U.S., India, Japan, U.K., France, Germany, Italy, And Spain

Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) stock is trading lower on Wednesday, in reaction to Centene Corp.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) decision to withdraw <a target="_blank" href="https://www.benzinga.com/markets/guidance/25/07/46209736/centene-withdraws-2025-guidance-shares-dive" rel="noreferrer noopener">its 2025 earnings guidance</a>.
This move by Centene has raised concerns across the health insurance sector, particularly regarding the individual Health Insurance Marketplace.
Centene&#8217;s withdrawal of its 2025 GAAP and adjusted diluted EPS guidance stems from its initial review of 2025 industry data from Wakely, an independent actuarial firm.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/46209736" rel="noreferrer noopener">Centene Withdraws 2025 Guidance, Shares Dive</a>
This data, covering 22 of Centene&#8217;s 29 Marketplace states and representing approximately 72% of their Marketplace membership, revealed two critical issues.
Firstly, overall market growth in these states is proving to be lower than anticipated. Secondly, and more significantly, the implied aggregate market morbidity, or the prevalence of illness, in these states is substantially higher than Centene&#8217;s original assumptions for risk adjustment revenue transfer.
This discrepancy has led Centene to estimate a preliminary reduction of approximately $1.8 billion in its full-year net risk adjustment revenue transfer expectation, which translates to an adjusted diluted EPS impact of around $2.75.
While withdrawing its comprehensive EPS guidance, Centene has reaffirmed its <a target="_blank" href="https://www.benzinga.com/25/02/43470058/insurance-firm-centenes-q4-earnings-enrollment-and-premium-boost-revenue-to-offset-lower-medicaid-enrollment-sticks-to-annual-forecast" rel="noreferrer noopener">fiscal year 2025 adjusted EPS</a> to be greater than $7.25, aligning with the consensus of $7.23.
It is worth noting that Centene had previously, in its <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45007934/insurer-centene-reports-better-than-expected-q1-earnings-on-strong-growth-in-commercial-plans-reaffirms-annual-profit-guidance" rel="noreferrer noopener">first-quarter earnings</a> release in April, raised its 2025 premium and service revenue guidance by $6 billion.
Centene now projects its 2025 premium and service revenue to be between $164 billion and $166 billion. This revised expectation is an increase from its earlier forecast of $158 billion to $160 billion.
The upward revision is attributed to two key factors: an additional $5 billion in Marketplace premium revenue, driven by stronger-than-expected enrollment during the first quarter, and an extra $1.0 billion in premium revenue due to outperformance in the Medicare Advantage annual enrollment period.
Oscar Health, despite this unsettling news from a peer, recently reported strong financial results for its first quarter. The company reported first-quarter revenue of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45246795/oscar-health-announces-strong-financial-results-for-first-quarter-2025-and-reaffirms-2025-guidance" rel="noreferrer noopener">approximately $3.0 billion</a>, up 42% year over year, beating the consensus of $2.86 billion. The increase was primarily due to higher membership.
Furthermore, Oscar Health&#8217;s earnings per share came in at 92 cents, exceeding the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 83 cents</a>. Oscar Health has reiterated its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43478082/oscar-health-announces-fourth-quarter-and-full-year-2024-results-introduces-full-year-2025-outlook" rel="noreferrer noopener">full-year 2025 outlook</a>, which was initially provided in its February financial results. The company continues to anticipate sales between $11.2 billion and $11.3 billion, with a projected medical cost ratio of 80.7%-81.7%.
The market&#8217;s reaction, evidenced by Oscar Health&#8217;s stock being down 15%, suggests that investors are interpreting Centene&#8217;s issues as potentially indicative of broader challenges within the individual health insurance marketplace.
Price Action: OSCR stock is trading lower by 15.0% to $17.38 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes" target="_blank" rel="noreferrer noopener">House Advances Trump&#8217;s &#8216;One Big Beautiful Bill&#8217; After Key Medicaid, Tax, And Border Security Changes</a></li>
</ul>
Image via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

OSCR

Centene's Guidance Withdrawal Spooks Sector, Oscar Health Stock Falls

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Oxy shares are trading higher after the company announced it secured a $22.5 million purchase order for its FDA-cleared ART100 system.

KNOP

KNOT Offshore Partners shares are trading higher after the company announced that it will acquire the Daqing Knutsen from Knutsen NYK Offshore Tankers AS.

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Wells Fargo analyst Elyse Greenspan maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Overweight and raises the price target from $37 to $42.

CRBG

Wells Fargo Maintains Overweight on Corebridge Financial, Raises Price Target to $42

General Dynamics Electric Boat, a business unit of General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), announced today that it was a­­­warded a $1.85 billion contract modification to a previously awarded contract supporting submarine production. This modification is for long lead time material and preliminary construction efforts for submarine production, as detailed in the June 26 U.S. Department of Defense <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4461409-1&amp;h=463130843&amp;u=https%3A%2F%2Fwww.defense.gov%2FNews%2FContracts%2FContract%2FArticle%2F4227676%2F&amp;a=contract+award+announcement">contract award announcement</a>.

Contracts

General Dynamics' Business Unit General Dynamics Electric Boat Bags $1.85B Contract Modification To Existing Contract Supporting Submarine Production

Econ #s

USA Gasoline Inventories 4.188M Barrel Build Vs 0.660M Barrel Build Est.

EIA Weekly Distillates Stocks 1.710M Barrel Draw Vs 1.650M Barrel Draw Est.

Northern Lights Fund Trust III Counterpoint Quantitative Equity ETF

Comments

Northern Lights Fund Trust III Counterpoint Quantitative Equity ETF

Actualités

Dernières nouvelles pour Northern Lights Fund Trust III Counterpoint Quantitative Equity ETF (NYSE:CPAI)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL